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Alzheimer’s disease (AD) pathology is characterized by the aggregation of beta-amyloid
(Aβ) and tau in the form of amyloid plaques and neurofibrillary tangles in the brain. It has
been found that a synergistic relationship between these two proteins may contribute
to their roles in disease progression. However, how Aβ and tau interact has not been
fully characterized. Here, we analyze how tau seeding or aggregation is influenced
by different Aβ self-assemblies (fibrils and oligomers). Our cellular assays utilizing tau
biosensor cells show that transduction of Aβ oligomers into the cells greatly enhances
seeded tau aggregation in a concentration-dependent manner. In contrast, transduced
Aβ fibrils slightly reduce tau seeding while untransduced Aβ fibrils promote it. We also
observe that the transduction of α-synuclein fibrils, another amyloid protein, has no
effect on tau seeding. The enhancement of tau seeding by Aβ oligomers was confirmed
using tau fibril seeds derived from both recombinant tau and PS19 mouse brain extracts
containing human tau. Our findings highlight the importance of considering the specific
form and cellular location of Aβ self-assembly when studying the relationship between
Aβ and tau in future AD therapeutic development.
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INTRODUCTION
The accumulation of amyloid plaques and neurofibrillary tangles in the brain are the two major
hallmarks of Alzheimer’s disease (AD) and are composed of the aggregated proteins β-amyloid
(Aβ) and tau, respectively. Misfolded Aβ can aggregate to form soluble oligomers and insoluble
fibrils (Glabe, 2008; Verma et al., 2015; Chiti and Dobson, 2017). Several studies have shown
that oligomeric and fibrillar species of Aβ contribute differently to disease progression (Dahlgren
et al., 2002; Li et al., 2014; Breydo and Uversky, 2015). For instance, Aβ oligomers, rather than
Aβ fibrils, have been shown to be cytotoxic to neurons and play a significant role in cell death
(Dahlgren et al., 2002).
Although the amyloid cascade hypothesis posits Aβ accumulation as the initiating toxic event
in AD, as reviewed by Hardy and Higgins (1992), the aggregation of tau, the other amyloid
protein associated with AD, has drawn increased attention recently (Jouanne et al., 2017). Studies
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of biomarkers from patients correlate neurodegeneration
and clinical decline to tau deposition independent of Aβ
accumulation (Tapiola et al., 2009; Rosenmann, 2012; Dickerson
et al., 2013). When tau aggregates into insoluble fibrils, these
fibrillar species can act as a seed to facilitate further conversion
of tau monomers into the fibrillar form (Kfoury et al., 2012;
Jackson et al., 2016; Fitzpatrick et al., 2017). Tau seeding has been
correlated with the development of tau pathology in the brain
(DeVos et al., 2018; Kaufman et al., 2018).
Here, we aim to study the linkage between Aβ self-assembly
and tau seeding. Many studies have analyzed the linkage of Aβ
and tau in the context of AD, as recently reviewed (Leinonen
et al., 2010; Ittner and Gotz, 2011; Bloom, 2014; Thal and
Fandrich, 2015). The synergistic interaction between Aβ and
tau has been highlighted in both animal models and biomarker
study in patients (Spires-Jones and Hyman, 2014; Bennett et al.,
2017; Busche et al., 2019). The animal model study has shown
the synergistic incensement of tau accumulation in the presence
of Aβ in the cortex of young tau (P301L)-overexpressed mice
(He et al., 2018; Vergara et al., 2019). Also, biomarker studies
in patients suggest that the progression to dementia is driven
by the interaction between Aβ and tau (Mulder et al., 2010;
Dickerson et al., 2013; Pascoal et al., 2017). Furthermore,
additional studies show that rather than just toxicity, Aβ can
lead to other cellular responses related to the development of tau
pathology, such as increased tau phosphorylation (Zheng et al.,
2002; Sun et al., 2008; Ma et al., 2009). However, the molecular
mechanism by which Aβ influences tau seeding and aggregation,
specifically which aggregate species of Aβ contributes most to this
process, is unknown.
To dissect the contributions different self-assemblies of Aβ
have on tau seeding, a method for quantitatively studying
tau seeding is needed. The HEK293T tau biosensor cell line
developed by Diamond and co-workers is capable of monitoring
and quantifying intracellular tau aggregation and seeding
(Holmes et al., 2014; Furman et al., 2015). Expressing tau
RD containing the disease-associated P301S substitution fused
to either cyan or yellow fluorescent proteins (CFP/YFP), the
biosensor cells produce a FRET signal upon aggregation of tau,
which can be quantified using flow cytometry. In this study, we
sought to explore how different Aβ assemblies might contribute
to the process of tau seeding. We use the biosensor cells to
measure the unique contributions of different assemblies of Aβ –
freshly prepared, oligomeric, and fibrillar – on tau seeding.
RESULTS
To determine the effects of different forms of amyloid beta
self-assemblies on intracellular tau seeding, we first generated
and characterized three forms of Aβ self-assemblies: freshly
prepared, oligomeric, and fibrillar. Recombinant Aβ42 was
expressed and purified as described previously (Jiang et al., 2013).
After purification, Aβ was diluted in PBS (10 µM), yielding a
sample composed of a single band and a mixture of several low
molecular weight higher-order assemblies, as assessed by native
PAGE (Supplementary Figure 1b). We term this sample “freshly
prepared” Aβ. After quiescent incubation at 37◦C for 18 h, the
Aβ aggregated into spherical oligomers, as shown by electron
microscopy (EM) (Figure 1B). After continued incubation for a
total of 100 h, the Aβ formed long, unbranched amyloid fibrils.
Aggregation was assessed by Thioflavin T (ThT) fluorescence
(Supplementary Figure 1a), which indicates the presence of
fibrillar Aβ.
To measure the effects of Aβ aggregates on intracellular tau
aggregation, we utilized tau HEK293T biosensor cells, which
express the repeat domain of tau (tau RD) with the P301S
mutation, fused with either yellow fluorescent protein (YFP)
or cyan fluorescent protein (CFP) (Holmes et al., 2014). Upon
aggregation of tau within the biosensor cell, the YFP and CFP
form a FRET pair, allowing for spectroscopic quantification of
the number of aggregates that form (Figure 1A). Cells were
initially transduced with different Aβ species (freshly prepared,
oligomeric, and fibrillar; Figure 1B) using lipofectamine,
followed by transduction of fibrillar tau RD seeds 24 h later.
After an additional 24 h, cells were imaged by fluorescent
microscopy, and they were then harvested for analysis by
flow cytometry 24 h after imaging. Without transduction of
any tau seeds, the biosensor cells show a diffuse fluorescent
signal, indicating background expression of non-aggregated
endogenous tau. Images of the biosensor cells seeded with tau RD
(10 nM) show intracellular tau aggregates in the form of bright
fluorescent puncta (Figure 1C). The number of visible puncta
greatly increases with a rising concentration of Aβ oligomers,
but a much smaller effect is observed with the freshly prepared
Aβ. Aβ fibrils appear to have a slight inhibitory effect on tau
seeding. These seeding effects were quantified by FRET-based
flow cytometry, which measures intracellular tau aggregation
using integrated FRET density (IFD, FRET intensity multiplied
by the percentage of FRET + cells). The flow data show that the
enhancement of tau seeding by Aβ oligomers is dose-dependent,
while the effects of freshly prepared and fibrillar Aβ are much
less obvious (Figure 1D). We then further characterized these
different effects by varying the amount of tau fibril seeds used in
the seeding assay. Cells were pretreated with the three different
Aβ species (100 nM) and increasing tau fibril seed concentrations
(1–200 nM). The effects of each Aβ species on tau seeding are
much more pronounced with higher tau seed concentrations: Aβ
oligomers enhance seeding, Aβ fibrils have an inhibitory effect,
and freshly prepared Aβ has little effect (Figure 1E). We also
performed a seeding experiment using Aβ treatment without
transfection reagent lipofectamine (Supplementary Figure 3).
When different concentrations of Aβ assemblies are added to
culture media without lipofectamine, Aβ fibrils and freshly
prepared Aβ promote tau seeding in a dose-dependent manner,
and Aβ oligomers show stronger promotion.
We further analyzed the effects of Aβ oligomers on the
promotion of tau seeding with a broader range of tau fibril
seed concentrations (Figure 2). Tau biosensor cells seeded
with increasing concentrations of tau RD display increased tau
aggregation as quantified by flow cytometry (Figure 2A) and
confirmed by fluorescent imaging (Figure 2B). The addition of
Aβ oligomers at 200 nM halves the amount of tau fibril seeds
needed to seed tau biosensor cells (EC50: 60 nM) as compared
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FIGURE 1 | Aggregate species (freshly prepared, oligomeric, fibrillar) of Aβ have distinct effects on tau seeding. (A) Schematic of HEK293T tau biosensor cell
seeding assay. Cells are transduced with Aβ, followed by tau fibril seeds 24 h later. Aggregation of tau can be detected by the presence of a FRET signal. (B) EM
images of Aβ self-assemblies (freshly prepared, oligomeric, and fibrillar) used in seeding experiments. (C) Fluorescent microscope images of seeded biosensor cells
taken in the green channel (ex. 488 nm, em. 520 nm). Background fluorescence (control, left panel) is diffuse non-aggregated YFP-tau. With the addition of tau
seeds, the endogenous tau aggregates into small discrete fluorescent puncta. Before the addition of tau fibril seeds, cells are pretreated with different self-assembly
forms of Aβ. (D) Flow cytometry quantification shows that increasing pretreatment concentrations of Aβ oligomers enhance intracellular tau aggregation seeded by
tau fibrils (50 nM), while freshly prepared Aβ has little effect. Aβ fibrils show slight inhibition of tau seeding. Seeding is measured by Integrated FRET Density (IFD).
(E) Tau seeding in biosensor cells seeded with increasing concentrations of tau fibrils and pretreated with different forms of Aβ. The data are presented as
mean ± SD (n = 9).
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FIGURE 2 | Tau seeding is specifically enhanced by Aβ, not α-synuclein.
(A) Tau seeding of biosensor cells pretreated with transduced α-synuclein
fibrils or Aβ oligomers as measured by Integrated FRET Density (IFD).
(B) Representative fluorescent images of treated tau biosensor cells. The data
are presented as mean ± SD (n = 9).
to cells with no pretreatment (EC50: 125 nM). We then sought to
determine if the effects of Aβ oligomers on tau seeding are specific
to Aβ or if other amyloid proteins might lead to similar seeding
enhancement. Pretreatment of biosensor cells with α-synuclein
fibrils (500 nM) showed no effect on tau seeded (EC50: 120 nM),
comparable to cells with no pretreatment. This indicates that tau
seeding is promoted by Aβ oligomers but not α-synuclein.
The generation of recombinant tau fibril seeds is traditionally
done in the presence of aggregation inducers such as heparin.
In our seeding experiments, fibril seeds were generated under
high protein concentration in the absence of any aggregation
inducer, as it has been reported that such molecules may have
complicated effects on tau aggregation and seeding. We aimed to
determine whether the promotion of tau seeding by Aβ oligomers
is dependent on heparin. To test this, we generated tau fibril
seeds grown in the presence of heparin and compared tau seeding
with and without heparin (Supplementary Figure 2). At low
concentrations of tau seed, the fibrils grown with heparin increase
seeding relative to fibrils without heparin. However, at high
concentrations, the seeding levels are similar. When cells are
pretreated with Aβ oligomers, the promotion of tau seeding is still
observed with and without heparin (Supplementary Figure 2c).
Following the observation that Aβ oligomers enhance
biosensor cell seeding with recombinant tau RD, we then
determined whether other forms of tau seeds lead to similar
effects. Brain extract of transgenic PS19 mice, expressing full-
length P301S human tau, was used as a tau seed. The seeds
were extracted from the mouse brains using previously published
methods (Jackson et al., 2016; Goedert and Spillantini, 2017). The
concentration of human tau in the brain extracts was quantified
using ELISA (see section “Materials and Methods”). Similar to
recombinant tau RD, the mouse brain extract seeding was greatly
enhanced by pretreatment with Aβ oligomers (Figure 3).
DISCUSSION
The aggregation of amyloid beta follows the conversion of
monomers into small soluble oligomers and then the eventual
growth of fibrils. The different aggregate species that are
generated in this aggregation process may have drastically
different biological effects. Previous work has indicated that
Aβ aggregates have different cytotoxicities and have unique
contributions to AD progression (Dahlgren et al., 2002; Heo
et al., 2007; Li et al., 2014). Our experiments quantitatively study
the effects of different Aβ aggregates on tau seeding, another
important contributor to AD pathology. We demonstrate that
internalized Aβ fibrils and oligomers are opposite in their effects
on tau seeding. Aβ oligomers show promotion of tau seeding
and fibrils show a reduction, while freshly prepared Aβ had
no obvious effects on seeding. It is possible that the observed
difference in tau seeding between Aβ fibril- and oligomer-treated
cells is a result of the potentially lower transfection efficiency of
Aβ fibrils compared to oligomers due to their larger size. We
observe that the addition of Aβ fibrils decreases the amount of
tau seeding not only relative to Aβ oligomers but also relative to
cells in which no Aβ was added. If this decrease in tau seeding
caused by Aβ fibrils is only due to lower transfection efficiency,
then we expect that the tau seeding with transfected Aβ fibrils
will be lower relative to with Aβ oligomers but greater or equal to
the seeding in cells with no Aβ. However, we observe that the tau
seeding with Aβ fibrils is lower than the levels in the cells with no
Aβ, indicating that the effects are not just due to concentration
and that the transfected Aβ fibrils have distinct effects on tau
seeding compared to oligomers.
To further explore the contribution of transfection efficiency,
we performed control seeding experiments without the use
of transfection reagent lipofectamine. Without the use of
lipofectamine to transfect the Aβ species into the cell, Aβ
oligomers and fibrils both enhance tau seeding (Supplementary
Figure 3). These findings agree with recent publications that have
focused on cross-seeding between Aβ and tau fibrils, in which
aggregated Aβ promotes the formation of tau aggregates (Stancu
et al., 2014; Bennett et al., 2017; He et al., 2018). Our in vitro
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FIGURE 3 | Aβ promotes tau seeding with brain extract from mice expressing
human full-length P301S tau. (A) Tau seeding of biosensor cells transduced
with PS19 mouse brain extract as measured by Integrated FRET Density (IFD).
The concentration of human tau in the brain extracts was quantified using
ELISA. The data are presented as mean ± SD (n = 6). (B) Representative
fluorescent images of treated tau biosensor cells.
cellular experiments show that transfected Aβ fibrils inhibit tau
seeding, while non-transfected Aβ fibrils enhance it. The results
of this study performed in a model cell system suggest that
intracellular and extracellular Aβ fibrils have opposite effects on
intracellular tau aggregation. This also highlights the fact that
the impact of Aβ on tau seeding is dependent on the location
of its aggregate form. This may have broader implications for
the nature of AD disease progression, in that the seeding of
tau aggregation and subsequent development of tau pathology is
dictated by which aggregate species of Aβ are present and where
they are located. This highlights the importance of considering
the location and type of amyloid species when developing assays
to design and screen therapeutics targeting Aβ and tau pathology.
Our cell culture model utilizes tau biosensor cells expressing
tau RD fused with CFP/YFP. The repeat domain has been
shown to contain the amyloid fibril core of tau, as supported
by the recently published tau paired-helical filament structure
from patient brains (Fitzpatrick et al., 2017; Falcon et al., 2018).
A potential limitation to this cell culture model could be present
if segments of tau outside of the RD (i.e., use of full-length
tau) contribute to seeding and fibrillization. Nevertheless, these
biosensor cells are a useful tool to assess tau seeding in vitro,
as they can be seeded with tau fibrils from various in vitro and
in vivo sources, both truncated and full-length (Sanders et al.,
2014; Kaufman et al., 2016).
Our study partially relies on the use of recombinant tau
fibrils to assess the role of Aβ on tau aggregation. Traditionally,
in vitro-generated tau fibrils are grown in the presence of heparin,
which is known to induce aggregation (Friedhoff et al., 1998;
King et al., 1999). Due to the complicated role of heparin on
the tau aggregation process, the application of tau seeds in the
presence of heparin may introduce confounding effects. Thus,
we attempted to explore the use of a heparin-free system in our
seeding experiments. In this study, we generated the recombinant
tau fibrils without the use of heparin, relying on relatively high
concentrations of tau monomer to facilitate aggregation. Growth
of tau fibrils without heparin displayed similar aggregation
kinetics as monitored by ThT fluorescence (Supplementary
Figure 2), and EM imaging shows long unbranched fibrils similar
in morphology to published images of tau RD with heparin
(Nizynski et al., 2018). Comparison of biosensor cells seeded
with tau fibrils grown in the presence or absence of heparin
show that both fibril preparations can seed the cells but that
the seeding capacities of each preparation are different. It is
possible that these observed differences in seeding are influenced
by the heparin. Using fibrils grown without heparin ensures that
the seeding effects measured in this study come directly from
tau fibrils. These findings demonstrate that it is practical to use
recombinant fibrils grown without heparin in future seeding and
aggregation studies, avoiding any potential complications with
the use of aggregation inducers.
MATERIALS AND METHODS
Aβ Expression and Purification
Aβ (1–42) was expressed and purified as described previously
(Jiang et al., 2013; Cao et al., 2018). The fusion protein of Aβ(1–
42) with maltose-binding protein (MBP – Aβ42) was expressed
using Escherichia coli BL21 plyS (DE3) cells and then purified
using a HisTrap HP column (GE healthcare). After overnight
cleavage by TEV protease, the uncleaved protein and TEV were
removed using Ni2+ affinity chromatography. The Aβ(1–42) in
the flow-through was purified by RP-HPLC and lyophilized. The
homogeneity of the Aβ sample was ensured by dissolving the
lyophilized powder in 60 mM NaOH and then fractionating
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it by SEC (GE, Superdex 200 Increase) in 20 mM NaOH to
eliminate pre-formed Aβ aggregates. The final concentration was
determined by a BCA assay, and the stock was stored at−80◦C.
Tau Expression and Purification
Human tau RD (residues 244–372) was expressed and purified
as described previously (Seidler et al., 2018). Briefly, BL21 (DE3
GOLD) competent E. coli cells and a pNG2 vector were used for
the expression of tau RD. After sonication, cell lysates were boiled
for 20 min and centrifuged to remove all insoluble proteins. The
remaining soluble protein was purified using a HighTrap SP ion-
exchange column (GE Healthcare), and fractions were analyzed
by SDS-PAGE/Coomassie blue staining. Enriched fractions were
further purified using a HiLoad 16/600 Superdex 75 SEC column
(GE Healthcare). Purified tau was concentrated to 50–100 mg/ml
and stored at−80◦C.
Thioflavin T Kinetics of Aβ Self-Assembly
Before the ThT kinetics assay, freshly SEC-fractionated Aβ was
mixed with 60 mM HCl to neutralize the NaOH in the stock
solution. The Aβ sample was then diluted in PBS to a final
concentration of 10 and 30 µM ThT (CalbioChem) was added.
The reaction mixture was filtered through a 0.2-µm filter and
immediately placed in a Corning 96-well Non-binding plate
(black, non-binding surface microplate) at 100 µl per well. The
ThT fluorescence signal was measured every 5 min in quiescent
conditions using a Fluostar Omega plate reader (BMG Labtech,
Offenburg, Germany) with excitation and emission wavelengths
of 440 and 490 nm, respectively, at 37◦C.
Thioflavin T Kinetics of Tau Aggregation
With and Without Heparin
Freshly purified tau RD was diluted in PBS containing 2 mM
DTT and 40 µM ThT to a final concentration of 200 µM in
the absence of any aggregation inducers (i.e., heparin). For tau
with heparin, sample tau RD (final concentration: 20 µM) was
diluted in PBS containing 2 mM DTT, 40 µM ThT, and heparin
(0.5 mg/ml). The reaction mixture was split into 3–4 replicates
and placed in 96-well plates (Corning 3881) at 100-µL well
volumes. ThT fluorescence intensity was measured every 15 min
with double orbital shaking at 37◦C in the same plate reader until
a plateau was reached.
Measurement of Tau Seeding Using
HEK293T Biosensor Cells
Tau RD P301S FRET Biosensor (ATCC CRL-3275) cells were
cultured and analyzed as described previously (Holmes et al.,
2014; Furman et al., 2015). Briefly, HEK293T cells were plated
on collagen-coated flat 96-well plates at a density of 2.5 × 104
cells/well in 200 µl of culture medium and incubated at 37◦C
in 5% CO2. After 24 h, the cells were transduced with different
self-assembly states of Aβ or sonicated α-synuclein fibrils. The
preparation of recombinant α-synuclein fibrils was performed as
described previously (Li et al., 2018). For protein transduction,
Aβ or α-synuclein was first diluted into Opti-MEM media
(GIBCO) at a 1:20 ratio, and LipofectamineTM 2000 (Thermo
Fisher Scientific) was also diluted in Opti-MEM at a 1:20 ratio.
The protein and lipofectamine dilutions were then mixed at equal
volumes and incubated for 15 min before application to cells. Tau
fibril seeds were transduced into the cells 24 h after Aβ/α-syn
transduction. Tau fibrils (tau RD and mouse brain extract)
were first diluted with Opti-MEM (1:20 ratio) and sonicated
for 10 min in an ultrasonic water bath then mixed with a 1:20
lipofectamine dilution and incubated for 15 min. Tau aggregation
in the biosensor cells was visualized by fluorescence microscopy
24 h after tau fibril seed transduction using the green channel
(ex: 485 nm; em: 520 nm). The cells were harvested 24 h after
imaging after extensive washing and treatment with trypsin. The
harvested cells were prepared in 200 µl of chilled buffer (HBSS,
1% FBS, 1 mM EDTA) and then stored at 4◦C until they were
analyzed by FRET-based flow cytometry.
Flow Cytometry and Data Analysis of Tau
Seeding
Intracellular protein aggregation of tau was quantified using
FRET-based flow cytometry with an adapted protocol (Furman
et al., 2015) using a Digital Analyzers LSRII (IMED) flow
cytometer. The fluorescence intensities of the FRET signal were
measured (ex: 405 nm; em: 525/50 nm), and CFP-fusion proteins
(ex: 405 nm; em: 405/50 nm) and YFP-fusion proteins (ex:
488 nm; em: 525/50 nm) alone were measured for background
subtraction. For each experiment, FRET signals of 20,000 cells
per replicate were analyzed. FRET gating was introduced to
exclude all FRET-negative cells and include the FRET-positive
cells. Integrated FRET density (IFD), defined as the percentage
of FRET-positive cells multiplied by the median fluorescence
intensity of FRET-positive cells, was calculated for all analyses.
Electron Microscopy
Aliquots of 3∼5 µl from aggregation reactions were taken at
different time points and applied to carbon-coated 400-mesh
Formvar grids (Electron Microscopy Science) that had been
glow-discharged using a Pelco Easy-Glow unit immediately
before sample application. The samples were stained with
2% uranyl acetate and analyzed using a JEOL JEM1200-EX
transmission electron microscope.
Animals
Animal care was conducted in compliance with the United States
Public Health Service Guide for the Care and Use of Laboratory
Animals, and the procedures were approved by the Institutional
Animal Care and Use Committee at the University of California,
Los Angeles. Eight-month-old P301S (PS19) transgenic mice on
(C57BL/6× C3H) F1 background mice were used for the study.
Preparation of Mouse Brain Extracts
Eight-month-old PS19 mice and age-matched WT mice were
deeply anesthetized with isoflurane (0.5–1.5 vol% in oxygen) and
sacrificed by decapitation. Brains were dissected and suspended
in 10% (w/v) ice-cold TBS containing protease and phosphatase
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inhibitors cocktail (ThermoFisher). The tissue was homogenized
at 4◦C using a probe sonicator (Omni Sonic Ruptor 250) at 30%
power using 25 pulses. Lysates were centrifuged at 21,000 × g
for 15 min to remove cell debris. Supernatants were aliquoted
and stored at −80◦C. Tau concentration was quantified using an
anti-tau ELISA kit (Invitrogen, cat# KHB0041) according to the
manufacturer’s instructions.
Statistical Analyses
All graphs were generated using Prism software ver. 7.0
(San Diego, CA, United States). The EC50 values and plots were
determined by fitting the data to a sigmoidal dose-response curve.
All FRET quantifications were conducted for a minimum of three
independent experiments, with at least three replicates in each
experimental condition.
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